A head-to-head study of insulin glargine (300 U/ml; Toujeo) versus insulin degludec (100 U/ml; Tresiba) in insulin-naïve adults with type 2 diabetes has found similar glycaemic control between the two second-generation basal insulin analogues. But the open-label, treat-to-target multinational BRIGHT study presented at the 2018 ADA Scientific Sessions in Orlando, Florida, found hypoglycaemic events were ...
Type 2 diabetes
Insulin glargine non-inferior to insulin degludec: BRIGHT
3 Jul 2018